Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1361

Shown on this page

Current sort

Live official records

Conditions: Eosinophilic Oesophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Mitral Valve Regurgitation
Interventions: Mitral valve repair, Transcatheter edge-to-edge repair; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 29
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 19 more

Conditions: Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Interventions: Exaluren; Drug
Lead sponsor: Eloxx Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 4 more

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: Avacopan, Placebo, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 62
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more

Conditions: Osseointegration Infection
Interventions: intraosseous antibiotic delivery; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more

Conditions: Lymphoma
Interventions: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate; Drug · Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 11 more

Conditions: T-cell NHL (PTCL or CTCL)
Interventions: KK2223; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Duarte, California • Orange, California • Stanford, California + 11 more

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Interventions: azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Relapsed or Refractory T Cell Lymphoma
Interventions: ONO-4685; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 17 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Intraosseous Antibiotics for Osseointegration

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

About this Penn Medicine (University of Pennsylvania) institution page